Neumora Therapeutics Inc header image

Neumora Therapeutics Inc

NMRA

Equity

ISIN null / Valor 129329732

NASDAQ (2026-09-25)
USD 0.68-3.63%

Neumora Therapeutics Inc
UMushroom community rating:

star star star star star
4.00 1 votes No rating yet
NegativeNeutralPositive

About company

Neumora Therapeutics Inc is a biotechnology firm dedicated to revolutionizing the treatment of brain diseases through innovative approaches in neuroscience. The company is at the forefront of developing medications aimed at addressing neuropsychiatric disorders and neurodegenerative diseases, which are known for their complexity and varied manifestations. Neumora's strategy involves targeting therapeutically relevant mechanisms within the central nervous system (CNS) with the goal of discovering treatments that are both novel and superior in their pharmacological effects. Additionally, the company employs a precision medicine framework to dissect the biological underpinnings of brain diseases, enabling the identification of specific patient groups who could benefit most from their therapies. This dual focus on groundbreaking pharmacology and targeted treatment approaches positions Neumora Therapeutics Inc as a key player in the quest to provide more effective solutions for conditions that have long challenged the medical community.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-60.1%1Y
-94.1%3Y
%5Y

Performance

123%1Y
142%3Y
142%5Y

Volatility

Market cap

127 M

Market cap (USD)

Daily traded volume (Shares)

2,315,967

Daily traded volume (Shares)

1 day high/low

11.47 / 10.87

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.00

1 votes
Performance:
starstarstarstarstar
4.00
Innovation:
starstarstarstarstar
5.00
Society:
starstarstarstarstar
5.00
Nature:
starstarstarstarstar
1.00
Viktor Stockel
Switzerland, 27 Oct 2025
star star star star star
Neumora Therapeutics focuses on precision neuroscience, developing therapies for depression, anxiety, and neurological disorders. Its AI-driven approach is innovative, addressing major unmet needs in mental health. High potential, but still early-stage and volatile.

EQUITIES OF THE SAME SECTOR

Tecan Group Ltd.
Tecan Group Ltd. Tecan Group Ltd. Valor: 1210019
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.11%CHF 223.20
Galenica Ltd.
Galenica Ltd. Galenica Ltd. Valor: 36067446
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.30%CHF 82.55
Siegfried Holding Ltd
Siegfried Holding Ltd Siegfried Holding Ltd Valor: 1428449
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.09%CHF 72.60
Ypsomed Holding AG
Ypsomed Holding AG Ypsomed Holding AG Valor: 1939699
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.39%CHF 360.40
AEVIS VICTORIA SA
AEVIS VICTORIA SA AEVIS VICTORIA SA Valor: 47863410
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.63%CHF 15.95
Outset Medical Inc
Outset Medical Inc Outset Medical Inc Valor: 56717137
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.56%USD 3.05
COSMO Pharmaceuticals N.V.
COSMO Pharmaceuticals N.V. COSMO Pharmaceuticals N.V. Valor: 32590356
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.44%CHF 55.90
Medartis Holding AG
Medartis Holding AG Medartis Holding AG Valor: 38620023
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.50%CHF 86.20
QuidelOrtho Corporation
QuidelOrtho Corporation QuidelOrtho Corporation Valor: 119356965
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.34%USD 10.94
Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc Xenon Pharmaceuticals Inc Valor: 25419823
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.94%USD 36.94